Literature DB >> 17225182

[18F-FDG-PET in therapy response of esophageal cancer].

H A Wieder1, K Herrmann, K Ott, B J Krause.   

Abstract

PET imaging with the glucose analog fluorodeoxyglucose (FDG-PET) has been evaluated in several studies to monitor tumor response in patients undergoing chemo- and radiotherapy. The clinical value of FDG-PET for differentiation of residual tumor and therapy induced fibrosis has been documented for esophageal cancer. Furthermore, there are now several reports suggesting that quantitative assessment of therapy induced changes in tumor FDG-uptake may allow prediction of tumor response and patient outcome very early in the course of therapy. This suggests that FDG-PET may be used to identify non-responders early during neoadjuvant chemoradiotherapy allowing for early modifications of the treatment protocol.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17225182     DOI： 10.1007/s00117-006-1461-9

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


  16 in total

1.  Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy.

Authors:  D R Jones; L A Parker; F C Detterbeck; T M Egan
Journal:  Cancer       Date:  1999-03-01       Impact factor: 6.860

Review 2.  Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.

Authors:  Marinke Westerterp; Henderik L van Westreenen; Johannes B Reitsma; Otto S Hoekstra; Jaap Stoker; Paul Fockens; Pieter L Jager; Berthe L F Van Eck-Smit; John T M Plukker; J Jan B van Lanschot; Gerrit W Sloof
Journal:  Radiology       Date:  2005-09       Impact factor: 11.105

3.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.

Authors:  W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

4.  Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer.

Authors:  G Zuccaro; T W Rice; J Goldblum; S V Medendorp; M Becker; R Pimentel; L Gitlin; D J Adelstein
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

5.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

6.  2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

Authors:  Stephen G Swisher; Jeremy Erasmus; Mary Maish; Arlene M Correa; Homer Macapinlac; Jaffer A Ajani; James D Cox; Ritsuko R Komaki; David Hong; Hoon K Lee; Joe B Putnam; David C Rice; W Roy Smythe; Linh Thai; Ara A Vaporciyan; Garrett L Walsh; Tsung-Teh Wu; Jack A Roth
Journal:  Cancer       Date:  2004-10-15       Impact factor: 6.860

7.  Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake.

Authors:  K Higashi; A C Clavo; R L Wahl
Journal:  J Nucl Med       Date:  1993-03       Impact factor: 10.057

8.  In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy.

Authors:  K Higashi; A C Clavo; R L Wahl
Journal:  J Nucl Med       Date:  1993-05       Impact factor: 10.057

Review 9.  Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

Authors:  Stephen G Swisher; Mary Maish; Jeremy J Erasmus; Arlene M Correa; Jaffer A Ajani; Robert Bresalier; Ritsuko Komaki; Homer Macapinlac; Reginald F Munden; Joe B Putnam; David Rice; W Roy Smythe; Ara A Vaporciyan; Garrett L Walsh; Tsung T Wu; Jack A Roth
Journal:  Ann Thorac Surg       Date:  2004-10       Impact factor: 4.330

10.  Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.

Authors:  Robert J Downey; Tim Akhurst; David Ilson; Robert Ginsberg; Manjit S Bains; Mithat Gonen; Heng Koong; Marc Gollub; Bruce D Minsky; Maureen Zakowski; Alan Turnbull; Steven M Larson; Valerie Rusch
Journal:  J Clin Oncol       Date:  2003-02-01       Impact factor: 44.544
View more
  1 in total

Review 1.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.